Dolby Laboratories, Inc. vs Roivant Sciences Ltd. Common Shares — how do they compare? Dolby Laboratories, Inc. trades at $58.47 (market cap $5.47B), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $25.09B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 4.6× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays a 2.47% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| DLB | ROIV | |
|---|---|---|
Market Cap | $5.47B | $25.09B |
Volume | 691,016 | 5,738,571 |
Sector | Technology | Health |
52-Week High | $70.09 | $41.81 |
52-Week Low | $48.51 | $16.04 |
Typical Hold Time | 98 Days | 0 Days |
Enterprise Value | $4.84B | $21.36B |
Dividend Yield | 2.47% | — |
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $58.35, down 0.19% with bearish technical signals despite strong profitability margins. The company maintains robust fundamentals with 87.61% gross margins and consistent earnings beats, though revenue has plateaued around $1.3B. Recent leadership transition to Marc Whitten and expanded Meta partnership for Dolby Atmos/Vision represent key developments. Technical indicators show resistance at $59 with support at $58.
DLB offers stable cash flow generation and dividend income but faces growth challenges with flat revenue. Analyst consensus targets $90.33 (55% upside) with 47% buy ratings, though near-term execution risks and licensing volatility warrant caution. The stock presents value for income investors but requires revenue acceleration for significant appreciation.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →